Serum amyloid A activates nuclear factor-κB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products

Journal of Rheumatology

Volumn 35, Issue 5, 2008, Pages 752-756

  Okamoto, Hiroshi ^a   Katagiri, Yukiko ^a   Kiire, Akiko ^a   Momohara, Shigeki ^a   Kamatani, Naoyuki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Receptor for advanced glycation end product; Rheumatoid arthritis; Serum amyloid A

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID A PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LUCIFERASE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NUCLEAR LOCALIZATION SIGNAL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; NF-KAPPA B; RECEPTORS, IMMUNOLOGIC; SERUM AMYLOID A PROTEIN; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 44349189334     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Maury CP. Reactive (secondary) amyloidosis and its pathogenesis. Rheumatol Int 1984;5:1-7.
2. Rocken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111-22.
3. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265:501-23.
4. Marhaug G, Dowton SB. Serum amyloid A: an acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol 1994;8:553-73.
5. DiBartola SP, Benson MD. The pathogenesis of reactive systemic amyloidosis. J Vet Intern Med 1989;3:31-41.
6. Hazenberg BP, van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 1994;8:661-90.
7. Mullan RH, Bresnihan B, Golden-Mason L, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through a NF-κB-dependent signal transduction pathway. Arthritis Rheum 2006;54:105-14.
8. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Makino H. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2006;54:97-104.
9. Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000;6:643-51.
10. Yang JP, Hori M, Sanda T, Okamoto T. Identification of a novel inhibitor of nuclear factor-κB, RelA-associated inhibitor. J Biol Chem 1999;274:15662-70.
11. Okamoto H, Cujec TP, Okamoto M, Peterlin BM, Baba M, Okamoto T. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 2000;272:402-8.
12. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999;37:381-8.
13. Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998;334:489-503.
14. Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol 2001;13:67-73.
15. O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2000;2:142-4.
16. Okamoto T. NF-κB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets 2006;6:359-72.
17. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62.
18. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-κB signaling by fenofibrate, a peroxisome proliferator activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005;23:323-30.
19. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005;83:876-86.
20. Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP. Advanced glycation end product receptor-mediated cellular dysfunction. Ann NY Acad Sci 2005;1043:676-80.
21. Simm A, Bartling B, Silber RE. RAGE: a new pleiotropic antagonistic gene? Ann NY Acad Sci 2004;1019:228-31.
22. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-91.
23. Yan, SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-97.
24. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995;96:1395-403.
25. Du Yan S, Zhu H, Fu J, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 1997;94:5296-301.
26. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781-90.
27. Pullerits R, Brisslert M, Jonsson IM, Tarkowski A. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via β2 integrin Mac-1. Arthritis Rheum 2006;54:3898-907.
28. Lee MS, Yoo SA, Cho CS, Suh PG, Kim WU, Ryu SH. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J Immunol 2006;177:5585-94.